Interferon plus amantadine versus interferon alone in the treatment of naı̈ve patients with chronic hepatitis C: a UK multicentre study (Q58324416)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

title

Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

1 reference

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

author name string

S Caronia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

M F Bassendine

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

R Barry

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

P Mills

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

N V Naoumov

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

R Fox

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

J Lowes

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

D Hollanders

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

L Murray-Lyon

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

R D Goldin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

G R Foster

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

UK Amantadine Study Group

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

publication date

1 October 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

512-516

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

2 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Inhibition of dengue virus replication by amantadine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Treatment of chronic hepatitis C with amantadine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Management of chronic hepatitis C: clinical audit of biopsy based management algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900140-4

7 January 2021

10.1016/S0168-8278(01)00140-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682036%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference